Business
Aeglea BioTherapeutics Announces Presentation of Additional Data from PEACE Phase 3 Study of Pegzilarginase for the Treatment of Arginase 1 Deficiency at the Society for Inherited Metabolic Disorders Annual Meeting
AUSTIN, Texas, March 29, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing a new generation
About this update from Spyre Therapeutics, Inc.
[{"type":"text","content":"AUSTIN, Texas, March 29, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced poster presentations at two upcoming medical meetings. The Company will present additional data from the PEACE Phase 3 study of pegzilarginase for the treatment of patients with Arginase 1 Deficiency (ARG1-D) at the Society for Inherited Metabolic Disorders (SIMD) Annual Meeting in Orlando, FL. Additionally, two encore posters describing the management of ARG1-D and the role of arginine as a key driver of the disease will be presented at the American Academy of Neurology (AAN) Annual Meeting in Seattle, WA and virtually.\n\n \n \n \n \n \n \n\n \nSociety for Inherited Metabolic Disorders Annual Meeting (April 10-13, 2022)Title: Pegzilarginase in Arginase 1 Deficiency: Results of the PEACE Pivotal Phase 3 Clinical TrialAbstract: #30Session: Scientific Session 5Presentation time: Monday, April 11 from 7-8pm PDTPresenter: Eric Bradford, MD, MSc, MBA, chief development officer at Aeglea BioTherapeutics\nAmerican Academy of Neurology Annual Meeting (Live: April 2-7, 2022; Virtual: April 24-26, 2022)Title: Management and Progression of Arginase 1 Deficiency Over 2 Decades of Follow-UpAbstract: 003Session: P11Presentation time: Tuesday, April 5 from 11:45am-12:45pm EDTPresenter: Deborah Marsden, MBBS, FAMCGG, MRCP(UK), attending physician, Division of Genetics and Genomics at Boston Children's Hospital\nTitle: Arginine: The Key Driver of Pathophysiology and Progression in Arginase 1 DeficiencyAbstract: 004Session: P11Presentation time: Tuesday, April 5 from 11:45am-12:45pm EDTPresenter: Mark Bechter, BM, vice president of medical affairs at Aeglea BioTherapeutics\nAbout Aeglea BioTherapeutics Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare metabolic diseases with limited treatment options. In December 2021, Aeglea announced positive topline data from its PEACE Phase 3 clinical trial for its lead product candidate, pegzilarginase, in patients with Arginase 1 Deficiency. Pegzilarginase has received both Rare Pediatric Disease and Breakthrough Therapy Designations. Aeglea also has an ongoing Phas...